YOLFTbeta
MaxCyte Inc

MaxCyte Inc

MXCT · NASDAQ · Healthcare / Medical Devices

1.19USD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1.19
Open1.16
Day Range1.12 – 1.20
52-Week Range0.6434 – 1.87
Volume1.25M
Market Cap120.75M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.34
Dividend Yield0.00%
Beta1.53
50-Day Avg1.21
200-Day Avg1.09

About

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Maher Masoud
  • Employees91
  • Headquarters9713 Key West Avenue, Rockville, MD, United States, 20850, USA
  • Websitehttps://www.maxcyte.com

Leadership

  • Mr. Maher MasoudPresident, CEO & Executive Director · b. 1976
  • Mr. Parmeet AhujaChief Financial Officer · b. 1969
  • Mr. Jay GelfmanChief Operations Officer
  • Ms. Jill MayerSenior Vice President of Human Resources

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue5.06M6.80M7.16M9.29M12.27M13.98M16.67M21.62M26.17M33.89M44.26M41.29M38.63M33.03M
Growth (%)-+34.50%+5.28%+29.67%+32.07%+13.98%+19.18%+29.72%+21.04%+29.52%+30.59%-6.72%-6.44%-14.50%
Cost of Revenue830.40K808.60K957.50K1.03M1.31M1.45M1.84M2.50M2.77M3.65M5.10M4.74M7.10M6.22M
Gross Profit4.23M6.00M6.21M8.26M10.96M12.53M14.83M19.12M23.40M30.25M39.16M36.55M31.53M26.80M
Gross Margin83.59%88.12%86.64%88.89%89.34%89.61%88.96%88.44%89.43%89.24%88.48%88.51%81.62%81.16%
Operating Expense6.19M6.80M7.48M9.02M13.69M21.82M23.25M31.54M34.46M48.44M66.52M84.84M82.72M72.09M
Operating Income-1.96M-804.70K-1.28M-761.10K-2.72M-9.29M-8.42M-12.42M-11.06M-18.19M-27.36M-48.30M-51.20M-45.28M
Operating Margin-38.79%-11.83%-17.81%-8.19%-22.20%-66.44%-50.55%-57.44%-42.25%-53.66%-61.82%-116.98%-132.54%-137.12%
EBITDA-1.81M-688.30K-1.18M-647.80K-2.60M-9.15M-7.91M-11.60M-9.94M-16.61M-20.75M-33.75M-36.27M-39.49M
EBITDA Margin-35.80%-10.11%-16.52%-6.97%-21.21%-65.42%-47.46%-53.65%-38.00%-49.02%-46.87%-81.75%-93.89%-119.57%
Net Income-1.99M-958.20K-1.84M-1.45M-3.35M-9.92M-8.87M-12.89M-11.82M-19.08M-23.57M-37.92M-41.05M-44.63M
Net Income Margin-39.30%-14.08%-25.64%-15.56%-27.27%-70.91%-53.21%-59.64%-45.15%-56.30%-53.25%-91.85%-106.29%-135.14%
R&D2.21M2.22M2.49M3.01M4.70M11.28M11.24M17.59M17.73M15.41M19.51M23.82M22.23M20.82M
R&D as % of Total Revenue43.62%32.56%34.76%32.38%38.28%80.69%67.46%81.37%67.77%45.46%44.09%57.69%57.54%63.05%
Interest Expense61.70K153.50K561.30K704.40K637.80K625.30K614.60K681.10K825.60K1.04M126.90K---
Interest Expense % of Total Revenue1.22%2.26%7.83%7.58%5.20%4.47%3.69%3.15%3.15%3.08%0.29%---

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.84M2.50M6.30M6.40M16.07M31.40M24.27M29.99M51.78M284.12M286.65M268.27M239.47M202.51M
Total Liabilities3.43M4.05M7.95M9.48M10.99M11.80M11.99M16.38M18.55M21.22M32.69M36.11M33.22M31.02M
Total Equity-590.70K-1.54M-1.65M-3.08M5.08M19.60M12.28M13.60M33.23M262.90M253.97M232.17M206.25M171.49M
Cash1.42M764.90K3.41M2.41M11.73M25.34M11.25M15.21M18.76M47.78M11.06M46.51M27.88M20.07M
Total Debt1.84M1.86M4.91M5.04M5.01M5.03M5.06M7.21M6.97M5.68M16.09M18.74M18.03M17.94M
Net Debt417.00K1.10M1.50M2.63M-6.72M-20.31M-6.19M-8.00M-11.79M-42.10M5.03M-27.76M-9.85M-2.12M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.13M-557.80K-1.93M-180.50K-2.33M-9.68M-10.49M-8.80M-8.78M-10.68M-14.78M-21.69M-27.61M-34.41M
Investing Cash Flow-11.50K-49.50K-147.00K-94.50K-218.80K-609.70K-3.83M454.50K-16.58M-195.01M-24.82M54.98M6.93M25.93M
Financing Cash Flow1.37M-46.30K4.72M-722.10K11.87M23.90M226.80K12.31M28.90M234.72M2.89M2.14M2.06M656.00K
Capital Expenditure17.40K49.50K147.00K94.50K218.80K609.70K709.70K1.27M2.07M3.83M18.48M3.70M1.65M1.77M
Free Cash Flow-2.14M-607.30K-2.07M-275.00K-2.55M-10.29M-11.20M-10.07M-10.85M-14.51M-33.26M-25.39M-29.26M-36.18M
FCF to OCF100.82%108.87%107.63%152.35%109.37%106.30%106.77%114.44%123.59%135.90%224.99%117.06%105.98%105.14%

Earnings

Report DateMar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 16, 2021Sep 13, 2021Nov 10, 2021Mar 22, 2022May 9, 2022Aug 10, 2022Nov 9, 2022Mar 15, 2023May 10, 2023Aug 9, 2023Nov 8, 2023Mar 12, 2024May 7, 2024Aug 6, 2024Nov 6, 2024Mar 11, 2025May 7, 2025Aug 6, 2025Nov 12, 2025Mar 24, 2026May 13, 2026Aug 12, 2026Nov 11, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00-0.10-0.06-0.05-0.05-0.07-0.07-0.08-0.07-0.11-0.10-0.10-0.07-0.13-0.13-0.12-0.12-0.10-0.10-0.10-0.08-0.07-0.12-0.08
EPS Actual-15.30-15.30-1.95-1.95-0.53-0.53-0.40-0.40-0.04-0.04-0.02-0.02-0.05-0.05-0.06-0.06-0.05-0.05-0.04-0.04-0.09-0.09-0.03-0.03-0.05-0.04-0.04-0.09-0.07-0.05-0.03-0.05-0.04-0.08-0.06-0.05-0.11-0.10-0.11-0.05-0.09-0.09-0.11-0.10-0.10-0.12-0.09-0.06-0.04-0.08-
Surprise----------------------------30.00%16.67%40.00%0.00%42.86%-14.29%25.00%28.57%0.00%0.00%-10.00%28.57%30.77%30.77%8.33%16.67%0.00%-20.00%10.00%25.00%31.69%33.33%-
Timing-----------------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap120.75M
Enterprise Value34.38M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.89
Price / Book0.77
EPS-0.34
Book Value1.50
Revenue (TTM)31.05M
Gross Profit (TTM)24.60M
EBITDA-30.29M
Profit Margin-114.77%
Operating Margin-140.72%
Return on Equity-20.39%
Return on Assets-10.64%
Shares Outstanding103.21M
Shares Float93.72M
Beta1.53
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 6 analystsTarget 4.11
  • Strong Buy
    6

Ownership Breakdown

Institutions
62.10%
Insiders
1.84%
Retail / Other
36.06%

Top Institutional Holders

  • BlackRock Inc
    8.80M8.53%
  • Capricorn Fund Managers Ltd
    8.20M7.95%
  • Vitruvian Partners
    5.04M4.89%
  • Vanguard Capital Management, LLC
    3.98M3.86%
  • Morgan Stanley - Brokerage Accounts
    3.69M3.57%
  • Mudita Advisors LLP
    3.37M3.27%
  • Brooklands Fund Management Limited
    2.85M2.76%
  • BNP Paribas Investment Partners SA
    2.77M2.69%
  • Geode Capital Management, LLC
    2.36M2.29%
  • Cadian Capital Management LP
    2.20M2.13%
  • State Street Corp
    2.19M2.13%
  • Peapod Lane Capital LLC
    2.13M2.06%
  • Renaissance Technologies Corp
    1.99M1.93%
  • Two Sigma Investments LLC
    1.46M1.42%
  • AQR Capital Management LLC
    1.22M1.18%

Top Fund Holders

  • AXA Framlington Health Fund - R Income
    2.77M2.69%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.74M2.66%
  • Liontrust UK Listed Smaller Coms B Acc
    2.73M2.64%
  • Unicorn AIM VCT Ord
    2.49M2.41%
  • Liontrust Instl UK Lstd Smlr Coms P Acc
    1.75M1.70%